Liver and aging‐1990. Edited by K. Kitani, 364 pp. Amsterdam; Excerpta Medica, 1991. $131.50
Raymond S. Koff, Hyman J. Zimmerman – 1 August 1992
Raymond S. Koff, Hyman J. Zimmerman – 1 August 1992
Seiichiro Kamimura, Karl Gaal, Robert S. Britton, Bruce R. Bacon, George Triadafilopoulos, Hidekazu Tsukamoto – 1 August 1992 – The precise role of lipid peroxidation in the pathogenesis of alcoholic liver disease is still being debated. To explore the issue, this study was undertaken to investigate the status of lipid peroxidation, antioxidants and prooxidants at two discrete stages of experimental alcoholic liver disease.
Staffan Sahlin, Jon Ahlberg, Eva Reihnér, Dagny Starhlberg, Kurt Einarsson – 1 August 1992 – The objective of this study was to investigate cholesterol metabolism in human gallbladder mucosa, especially in relation to hepatic cholesterol metabolism, gallstone disease and treatment with bile acids. Gallbladder mucosa and liver tissue samples were collected in 44 patients undergoing cholecystectomy; 30 had cholesterol gallstones and the rest were stone free.
1 August 1992
Javier González, Johan Fevery – 1 August 1992 – Chemically induced diabetes has been reported to induce profound changes in bile formation, but possible toxic effects of the streptozotocin or alloxan used cannot be excluded totally. This study was undertaken to evaluate biliary function in spontaneously diabetic female biobreeding rats with a diabetes duration of 2 wk and compare them with nondiabetic littermates. Diabetic animals evidenced glycosuria, hyperglycemia and hypoinsulinemia.
Ramón Vilana, Jordi Bruix, Concepció Bru, Carmen Ayuso, Manel Solé, Joan Rodés – 1 August 1992 – This study was aimed at defining the therapeutic value of percutaneous ethanol injection in patients with solitary hepatocellular carcinoma less than 4 cm. Ultrasound‐guided ethanol injection was performed in 24 cirrhotic patients (9 Child A, 10 Child B and 5 Child C), with hepatocellular carcinoma not suitable for surgical treatment. Its efficacy was assessed by repeated ultrasound, computed tomography and tumor biopsy during a follow‐up ranging between 4 and 41 mo.
Naoki Hiramatsu, Norio Hayashi, Yoshimichi Haruna, Akinori Kasahara, Hideyuki Fusamoto, Chisato Mori, Isao Fuke, Hiroto Okayama, Takenobu Kamada – 1 August 1992 – The localization of hepatitis C virus–infected hepatocytes in the human liver remains unclear despite the development of a serological assay for the antibody to hepatitis C virus. We studied their localization immunohistochemically with monoclonal antibodies to core, envelope and NS3 antigens of hepatitis C virus.
Teresa L. Wright – 1 August 1992
C. Minke Bakker, Herold J. Metselaar, Theo N. Groenland, Maria J. Gomes, Eduard A. R. Knot, Eric J. Hesselink, Solco W. Schalm, Jeanne Stibbe, Onno T. Terpstra – 1 August 1992 – The major cause of the increased tissue‐type plasminogen activator activity during orthotopic liver transplantation is still unclear. Both the lack of hepatic clearance of tissue‐type plasminogen activator in the anhepatic period and increased endothelial release from the graft on reperfusion have been proposed as the major causes.